EpiBiologics

San Mateo, United States

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

$107.0M raised

Jan 2026

Series B

Top Investors

Vivo CapitalSamsara BioCapitalPolaris PartnersMission BioCapitalDigitalis Ventures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has EpiBiologics raised?

EpiBiologics has raised $107.0M in total funding. The most recent round was Series B. The last funding was announced in January 2026.

Who are EpiBiologics's investors?

EpiBiologics's investors include Vivo Capital, Samsara BioCapital, Polaris Partners, Mission BioCapital, Digitalis Ventures.

Where is EpiBiologics headquartered?

EpiBiologics is headquartered in San Mateo, United States.

What does EpiBiologics do?

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

What stage is EpiBiologics at?

EpiBiologics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 8, 2026.

MLA

"EpiBiologics — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/epibiologics. Accessed June 3, 2026.

APA

VCBacked. (2026). EpiBiologics — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/epibiologics

Wikipedia (cite web)

{{cite web |title=EpiBiologics — Funding & Investors |url=https://www.vcbacked.co/company/epibiologics |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 8, 2026.